Search Results - "Melanoma/mortality"

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study

Authors: Mark Schuiveling Laurens S Ter Maat Isabella A J Van Duin et al.

Source: J Natl Cancer Inst
Journal of the National Cancer Institute, 117, 6, pp. 1245-1252
Journal of the National Cancer Institute, vol. 117, no. 6, pp. 1245-1252

Subject Terms: Humans, Melanoma/drug therapy, Melanoma/mortality, Melanoma/pathology, Male, Female, Immune Checkpoint Inhibitors/therapeutic use, Body Composition, Middle Aged, Aged, Body Mass Index, Retrospective Studies, Tomography, X-Ray Computed, Adult, Treatment Outcome, Progression-Free Survival, Aged, 80 and over, Netherlands/epidemiology, Skin Neoplasms/drug therapy, Skin Neoplasms/mortality, Skin Neoplasms/pathology, Intra-Abdominal Fat, Muscle, Skeletal/diagnostic imaging, Subcutaneous Fat, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Medical Oncology - Radboud University Medical Center, Article

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39980388
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/320183
https://doi.org/10.1093/jnci/djaf039
https://repository.ubn.ru.nl//bitstream/handle/2066/320183/320183.pdf
https://hdl.handle.net/2066/320183
https://serval.unil.ch/notice/serval:BIB_3415CBA985BE
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_3415CBA985BE8
https://serval.unil.ch/resource/serval:BIB_3415CBA985BE.P001/REF.pdf

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study

Authors: Jonathan S. Zager Marlana Orloff Pier Francesco Ferrucci et al.

Source: Ann Surg Oncol

Subject Terms: Male, Uveal Neoplasms, Adult, Aged, 80 and over, Liver Neoplasms, Middle Aged, Prognosis, Female [MeSH], Follow-Up Studies [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Adult [MeSH], Humans [MeSH], Drug Delivery Systems [MeSH], Melanoma/secondary [MeSH], Uveal Neoplasms/drug therapy [MeSH], Melphalan/administration, Antineoplastic Agents, Alkylating/therapeutic use [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Survival Rate [MeSH], Male [MeSH], Liver Neoplasms/secondary [MeSH], Melanoma/pathology [MeSH], Prognosis [MeSH], Antineoplastic Agents, Alkylating/administration, Hepatobiliary Tumors, Uveal Neoplasms/pathology [MeSH], Melanoma/drug therapy [MeSH], Liver Neoplasms/drug therapy [MeSH], Uveal Neoplasms/mortality [MeSH], Survival Rate, 03 medical and health sciences, Drug Delivery Systems, 0302 clinical medicine, Uveal Melanoma, Humans, Female, Melanoma, Melphalan, Antineoplastic Agents, Alkylating, Aged, Follow-Up Studies

Access URL: https://pubmed.ncbi.nlm.nih.gov/38704501
https://repository.publisso.de/resource/frl:6504059

Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?

Authors: Nielsen, Jesper Bo Kristiansen, Ivar Sønbø Thapa, Subash

Source: British Journal of Dermatology. 191:365-374

Subject Terms: Male, Adult, Skin Neoplasms, Melanoma/mortality, Overdiagnosis, Adolescent, Ultraviolet Rays, Denmark, Biopsy, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Ultraviolet Rays/adverse effects, Humans, Skin Neoplasms/mortality, Registries, Child, Melanoma, Aged, Incidence, Registries/statistics & numerical data, Middle Aged, Denmark/epidemiology, Overdiagnosis/statistics & numerical data, Sunlight/adverse effects, Sunlight, Female

Access URL: https://pubmed.ncbi.nlm.nih.gov/38655629

The obesity survival paradox and melanoma-related mortality

Authors: Arbel, Yuval ארבל, יובל Kerner, Amichai et al.

Contributors: Arbel, Yuval ארבל, יובל Kerner, Amichai et al.

Source: Israel Affairs. 29,5 (2023) 1057-1066

Subject Terms: Melanoma -- Mortality -- Israel, Obesity -- Israel

Access URL: https://uli.nli.org.il/discovery/search?query=issn,exact,1353-7121&tab=LibraryCatalog&search_scope=MyInstitution&vid=972NNL_ULI_C:MAIN

Autonomous All-in-One Patch for Closed-Loop Diagnosis–Therapy of Melanoma

Authors: Lihao Guo Fengqi Zhang Li Wang et al.

Subject Terms: Genetics, Pharmacology, Biotechnology, Developmental Biology, Cancer, Space Science, Biological Sciences not elsewhere classified, tumor inhibitory rate, insufficient medical resources, induced side effects, controllably release drugs, term precision medicine, drug release unit, melanoma mortality rates, melanoma early diagnosis, system might shed, term monitoring, drug delivery, smart control, significantly impacting, several units, sensitively diagnosed, second day, real time, power supply, one patch, new light, interstitial fluid, including sensing, flexible printed

Availability: https://doi.org/10.1021/acssensors.5c00791.s001
https://figshare.com/articles/journal_contribution/Autonomous_All-in-One_Patch_for_Closed-Loop_Diagnosis_Therapy_of_Melanoma/29203422

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma:Comparison of 3-year data from PRADO and OpACIN-neo

Authors: Reijers, Irene L M Menzies, Alexander M Lopez-Yurda, Marta et al.

Source: Reijers, I L M, Menzies, A M, Lopez-Yurda, M, Versluis, J M, Rozeman, E A, Saw, R P M, van Houdt, W J, Kapiteijn, E, van der Veldt, A A M, Suijkerbuijk, K P M, Eriksson, H, Hospers, G A P, Klop, W M C, Torres Acosta, A, Grijpink-Ongering, L, Gonzalez, M, van der Wal, A, Al-Mamgani, A, Spillane, A J, Scolyer, R A, van de Wiel, B A, van Akkooi, A C J, Long, G V & Blank, C U 2025, 'Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma ....

Subject Terms: Humans, Melanoma/mortality, Neoadjuvant Therapy/mortality, Male, Female, Middle Aged, Neoplasm Staging, Ipilimumab/therapeutic use, Aged, Chemotherapy, Adjuvant, Skin Neoplasms/mortality, Lymph Node Excision, Immune Checkpoint Inhibitors/therapeutic use, Adult, Immunotherapy/methods, Nivolumab/therapeutic use, Precision Medicine/methods, Antineoplastic Combined Chemotherapy Protocols/therapeutic use

File Description: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/39602990; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/a7d83797-0e77-4e1c-9d50-d1c472e1262c; info:eu-repo/semantics/altIdentifier/pissn/0959-8049; info:eu-repo/semantics/altIdentifier/eissn/1879-0852

Availability: https://hdl.handle.net/11370/a7d83797-0e77-4e1c-9d50-d1c472e1262c
https://research.rug.nl/en/publications/a7d83797-0e77-4e1c-9d50-d1c472e1262c
https://doi.org/10.1016/j.ejca.2024.115141
https://pure.rug.nl/ws/files/1277673260/1-s2.0-S0959804924017489-main.pdf
https://www.scopus.com/pages/publications/85210014804

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

Authors: Dimitriou, F. Orloff, M.M. Koch Hein, E.C. et al.

Source: European journal of cancer, vol. 214, pp. 115161

Subject Terms: Humans, Uveal Neoplasms/drug therapy, Uveal Neoplasms/genetics, Uveal Neoplasms/pathology, Uveal Neoplasms/mortality, Melanoma/drug therapy, Melanoma/genetics, Melanoma/secondary, Melanoma/mortality, Melanoma/pathology, Male, Female, Middle Aged, Immune Checkpoint Inhibitors/therapeutic use, Aged, GTP-Binding Protein alpha Subunits, Gq-G11/genetics, Retrospective Studies, Adult, GTP-Binding Protein alpha Subunits/genetics, Mutation, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, 80 and over, GNA11, GNAQ, Immune checkpoint inhibitors, Tebentafusp, Uveal melanoma

File Description: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/39647344; info:eu-repo/semantics/altIdentifier/eissn/1879-0852; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_9D2AD18E0E656; https://serval.unil.ch/notice/serval:BIB_9D2AD18E0E65; https://serval.unil.ch/resource/serval:BIB_9D2AD18E0E65.P001/REF.pdf

Availability: https://serval.unil.ch/notice/serval:BIB_9D2AD18E0E65
https://doi.org/10.1016/j.ejca.2024.115161
https://serval.unil.ch/resource/serval:BIB_9D2AD18E0E65.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_9D2AD18E0E656

Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022)

Authors: Pedersen, Sidsel Johansen, Emma Lund Højholt, Karen Louise et al.

Source: Pedersen, S, Johansen, E L, Højholt, K L, Pedersen, M W, Mogensen, A M, Petersen, S K, Haslund, C A, Donia, M, Schmidt, H, Bastholt, L, Friis, R, Svane, I M & Ellebaek, E 2025, 'Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022)', European Journal of Cancer, vol. 217, 115253. https://doi.org/10.1016/j.ejca.2025.115253

Subject Terms: Adult, Aged, 80 and over, Brain Neoplasms/secondary, Denmark/epidemiology, Female, Humans, Immune Checkpoint Inhibitors/therapeutic use, Male, Melanoma/mortality, Meningeal Neoplasms/secondary, Middle Aged, Radiosurgery, Retrospective Studies, Targeted therapy, Melanoma brain metastases, Leptomeningeal disease, Immunotherapy, Postoperative stereotactic radiosurgery, Real-world evidence

File Description: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/39874911; info:eu-repo/semantics/altIdentifier/pissn/0959-8049

Availability: https://vbn.aau.dk/da/publications/038d896a-b4b3-4e32-8750-c9daf6454d41
https://doi.org/10.1016/j.ejca.2025.115253
https://vbn.aau.dk/ws/files/768135816/Pedersen_et_al._2025_._Survival_improvements_in_patients_with_melanoma_brain_metastases_and_leptomeningeal_disease_in_the_modern_era_Insights_from_a_nationwide_study_2015_2022_.pdf
https://www.scopus.com/pages/publications/85215949615

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma

Authors: Jeffrey Weber Waqas Haque Svetomir N Markovic et al.

Source: Oncologist
The oncologist, vol. 30, no. 3

Subject Terms: 03 medical and health sciences, 0302 clinical medicine, Humans, Oximes/administration & dosage, Oximes/therapeutic use, Oximes/pharmacology, Melanoma/drug therapy, Melanoma/genetics, Melanoma/pathology, Melanoma/mortality, Male, Female, Middle Aged, Imidazoles/therapeutic use, Imidazoles/administration & dosage, Imidazoles/pharmacology, Proto-Oncogene Proteins B-raf/genetics, Pyrimidinones/administration & dosage, Pyrimidinones/therapeutic use, Pyrimidinones/pharmacology, Pyridones/administration & dosage, Pyridones/therapeutic use, Pyridones/pharmacology, Retrospective Studies, Adult, Aged, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Chemotherapy, Adjuvant/methods, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Skin Neoplasms/genetics, Skin Neoplasms/mortality, Mutation, Disease-Free Survival, BRAF mutation, dabrafenib, melanoma, relapse-free survival, trametinib, Melanoma and Cutaneous Malignancies

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39560953
https://serval.unil.ch/notice/serval:BIB_A8A26871D41B
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_A8A26871D41B1
https://serval.unil.ch/resource/serval:BIB_A8A26871D41B.P001/REF.pdf

Comprehensive analysis of aberrantly methylated differentially expressed genes and validation of CDC6 in melanoma

Authors: Liao, Li Han, Wei Shen, Yue et al.

Source: J Cancer Res Clin Oncol

Subject Terms: 0301 basic medicine, 0303 health sciences, Skin Neoplasms, Research, Gene Expression Profiling, Nuclear Proteins, Cell Cycle Proteins, DNA Methylation, Prognosis, Gene Expression Regulation, Neoplastic, 03 medical and health sciences, Melanoma, Cutaneous Malignant, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic [MeSH], Melanoma, Cutaneous Malignant [MeSH], Biomarkers, Female [MeSH], CDC6, Cell Cycle Proteins/genetics [MeSH], Melanoma/genetics [MeSH], Humans [MeSH], Protein Interaction Maps/genetics [MeSH], Skin Neoplasms/pathology [MeSH], Metastatic, Melanoma/mortality [MeSH], Skin Neoplasms/genetics [MeSH], DNA Methylation [MeSH], Melanoma/pathology [MeSH], Biomarkers, Tumor/genetics [MeSH], Prognosis [MeSH], Cell Cycle Proteins/metabolism [MeSH], DNA methylation, SKCM, Gene Expression Profiling [MeSH], Nuclear Proteins [MeSH], Humans, Female, Protein Interaction Maps, Melanoma

Access URL: https://pubmed.ncbi.nlm.nih.gov/39052109
https://repository.publisso.de/resource/frl:6501142

Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with diabetes: a systematic review and meta-analysis

Authors: Tønder, Jens Ejrnæs Bønnelykke-Behrndtz, Marie Louise Laurberg, Tinne et al.

Source: BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Tønder, J E, Bønnelykke-Behrndtz, M L, Laurberg, T, Røssell, E-L & Sollie, M 2024, 'Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with diabetes : a systematic review and meta-analysis', BMC Cancer, vol. 24, 812. https://doi.org/10.1186/s12885-024-12598-8

Subject Terms: Skin Neoplasms, Melanoma/mortality, Diabetes Mellitus, Type 2/complications, Incidence, Diabetes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Type 2 diabetes, 3. Good health, Meta-analysis, Diabetes Mellitus, Type 2, Risk Factors, Systematic review, Humans, Skin Neoplasms/mortality, Systematic Review, Melanoma, RC254-282, Cancer, Neoplasm Staging

Access URL: https://pubmed.ncbi.nlm.nih.gov/38972968
https://doaj.org/article/22b4698b8252480398d0aecbcfadacc7

Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients

Authors: A. Gawaz I. Wolff L. Nanz et al.

Source: Cancer Immunol Immunother

Subject Terms: Male, Aged, 80 and over, Skin Neoplasms, Research, Aged, 80 and over [MeSH], Melanoma, ≥ 75 years, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Elderly patients, Melanoma/drug therapy [MeSH], Female [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Melanoma/immunology [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Immune checkpoint inhibitor, Skin Neoplasms/mortality [MeSH], Nivolumab/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Middle Aged, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Chemotherapy, Adjuvant, Humans, Female, Immune Checkpoint Inhibitors, Aged, Retrospective Studies

Access URL: https://pubmed.ncbi.nlm.nih.gov/38969911
https://repository.publisso.de/resource/frl:6524688

High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial).

Authors: De Smedt, Julie Van Kelst, Sofie Janssen, Laudine et al.

Source: British Journal of Dermatology, 191 (6), 886 - 896 (2024-11-18)

Subject Terms: Vitamin D, 25-hydroxyvitamin D, Cholecalciferol, Vitamins, Humans, Female, Male, Double-Blind Method, Middle Aged, Aged, Adult, Prospective Studies, Cholecalciferol/administration & dosage, Cholecalciferol/adverse effects, Treatment Outcome, Neoplasm Recurrence, Local/prevention & control, Neoplasm Recurrence, Local/epidemiology, Vitamins/administration & dosage, Melanoma/mortality, Melanoma/drug therapy, Skin Neoplasms/mortality, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Vitamin D/administration & dosage, Vitamin D/blood, Vitamin D/analogs & derivatives, Dietary Supplements, Melanoma, Neoplasm Recurrence, Local, Skin Neoplasms, Dermatology, Human health sciences, Sciences de la santé humaine, Dermatologie

Relation: https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae257/58941454/ljae257.pdf; urn:issn:0007-0963; urn:issn:1365-2133

Access URL: https://orbi.uliege.be/handle/2268/335730

International melanoma and non melanoma skin cancer mortality trends: is it time to refocus our attention?

Authors: Zoe C Venables Sonia Gran Nick J Levell et al.

Source: Venables, Z C, Gran, S, Levell, N J, Yiu, Z Z N & Proby, C M 2024, 'International melanoma and non-melanoma skin cancer mortality trends-is it time to re-focus our attention?', Clinical and Experimental Dermatology, vol. 49, no. 5, pp. 514-516. https://doi.org/10.1093/ced/llad438

Subject Terms: Global Health/statistics & numerical data, Male, Skin Neoplasms, Melanoma/mortality, Humans, Female, Skin Neoplasms/mortality, Mortality, Mortality/trends, Global Health, Melanoma, 3. Good health

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38060677

Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade

Authors: Miriam Mengoni Andreas Dominik Braun Mattes Simon Hinnerichs et al.

Source: J Cancer Res Clin Oncol

Subject Terms: Male, Adult, Aged, 80 and over, Skin Neoplasms, Research, Middle Aged, Prognosis, 03 medical and health sciences, 0302 clinical medicine, Chemotherapy, Adjuvant, Body Composition, Humans, Female, Muscle, Skeletal, Tomography, X-Ray Computed, Melanoma, Immune Checkpoint Inhibitors, Melanoma/therapy [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Muscle, Skeletal/diagnostic imaging [MeSH], Skin Neoplasms/drug therapy [MeSH], Low skeletal muscle mass, Tomography, X-Ray Computed [MeSH], Male [MeSH], Muscle, Skeletal/pathology [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Melanoma/pathology [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Melanoma/mortality [MeSH], Body Composition [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Immunotherapy, Prognosis [MeSH], Skin Neoplasms/mortality [MeSH], Body composition, Retrospective Studies, Aged

Access URL: https://pubmed.ncbi.nlm.nih.gov/38796605
https://repository.publisso.de/resource/frl:6492801

Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study: A nationwide cohort study

Authors: Not, O.J. van Meza, M.M. de Eertwegh, A.J.M. van den et al.

Contributors: Not, O.J. van Meza, M.M. de Eertwegh, A.J.M. van den et al.

Source: van Not, O J, de Meza, M M, van den Eertwegh, A J M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, van Breeschoten, J, de Groot, J-W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Bonenkamp, H J, Boers-Sonderen, M J, Blokx, W A M, Wouters, M W J M & Suijkerbuijk, K P M 2022, 'Response to immune checkpoint inhibitors in acral melanoma : A nationwide cohort study', European Journal of Cancer, vol. 167, pp. 70-80. https://doi.org/10.1016/j.ejca.2022.02.026
European Journal of Cancer, 167, pp. 70-80

Subject Terms: Radboudumc 18: Healthcare improvement science RIHS: Radboud Institute for Health Sciences, 0301 basic medicine, Cancer Research, Skin Neoplasms, Survival, Melanoma/mortality, THERAPY, SUBTYPES, Cohort Studies, Immune checkpoint inhibitors, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Melanoma, Cutaneous Malignant, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Skin Neoplasms/drug therapy, Journal Article, Humans, Prospective Studies, Immune Checkpoint Inhibitors, Melanoma, OUTCOMES, IPILIMUMAB, Response, KIT, Radboudumc 14: Tumours of the digestive tract RIHS: Radboud Institute for Health Sciences, EFFICACY, Nivolumab/adverse effects, Immune Checkpoint Inhibitors/therapeutic use, Ipilimumab, 3. Good health, MUCOSAL, Nivolumab, Oncology, ARM, Immunotherapy, Ipilimumab/therapeutic use

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/35395553
https://pure.eur.nl/en/publications/1281252e-ffc9-4c63-a584-5f4f694e5c5d
https://doi.org/10.1016/j.ejca.2022.02.026
https://research.rug.nl/en/publications/4eaf37d0-e9eb-444d-8275-f8aa051f3a33
https://hdl.handle.net/11370/4eaf37d0-e9eb-444d-8275-f8aa051f3a33
https://doi.org/10.1016/j.ejca.2022.02.026
https://cris.maastrichtuniversity.nl/en/publications/5c12b11e-cf71-4548-bdb5-f7e35804eab7
https://doi.org/10.1016/j.ejca.2022.02.026
https://research.vumc.nl/en/publications/9ea06a14-8ccd-4a3b-b117-2eb77a7569be
https://dspace.library.uu.nl/handle/1874/446113
https://hdl.handle.net/1887/3563996
https://pure.amsterdamumc.nl/en/publications/f1f99c61-5388-40ac-9168-81365e273462
https://doi.org/10.1016/j.ejca.2022.02.026
https://repository.ubn.ru.nl/handle/2066/250273
https://repository.ubn.ru.nl//bitstream/handle/2066/250273/250273.pdf

Obstructive sleep apnea and cancer: epidemiology, pathophysiology, and clinical aspects

Authors: Castrogiovanni A. Modica D. M. Amata M. et al.

Source: Minerva Respiratory Medicine. 63

Subject Terms: Biomarkers, Hypoxia, Melanoma, Mortality, Sleep deprivation

File Description: application/pdf

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

Authors: Verheijden, R.J. Burgers, F.H. Janssen, J.C. et al.

Source: European journal of cancer, vol. 207, pp. 114172

Subject Terms: Humans, Male, Female, Melanoma/drug therapy, Melanoma/immunology, Melanoma/mortality, Immunosuppressive Agents/adverse effects, Immunosuppressive Agents/therapeutic use, Immune Checkpoint Inhibitors/adverse effects, Middle Aged, Aged, Adrenal Cortex Hormones/therapeutic use, Adrenal Cortex Hormones/adverse effects, Adult, Retrospective Studies, Skin Neoplasms/drug therapy, Skin Neoplasms/immunology, Skin Neoplasms/mortality, 80 and over, Checkpoint inhibitor, Corticosteroids, Immune-related adverse events, Immunosuppression, Melanoma, Toxicity

File Description: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/38905818; info:eu-repo/semantics/altIdentifier/eissn/1879-0852; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_AB4D3ADF8F4A8; https://serval.unil.ch/notice/serval:BIB_AB4D3ADF8F4A; https://serval.unil.ch/resource/serval:BIB_AB4D3ADF8F4A.P001/REF.pdf

Availability: https://serval.unil.ch/notice/serval:BIB_AB4D3ADF8F4A
https://doi.org/10.1016/j.ejca.2024.114172
https://serval.unil.ch/resource/serval:BIB_AB4D3ADF8F4A.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_AB4D3ADF8F4A8

Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA

Authors: C. Posch Christian Diehl Bernhard Meyer et al.

Source: Clin Transl Oncol
Clin. Transl. Oncol. 23, 2020-2029 (2021)

Subject Terms: Adult, Aged, 80 and over, Male, Proto-Oncogene Proteins B-raf, Brain Neoplasms, Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Proto-Oncogene Proteins B-raf/genetics [MeSH], GPA, Radiosurgery, Prognostic factors, Radiosurgery/methods [MeSH], Radiosurgery/adverse effects [MeSH], Brain metastases, Melanoma/diagnostic imaging [MeSH], Male [MeSH], Brain Neoplasms/mortality [MeSH], Research Article, Karnofsky Performance Status [MeSH], Female [MeSH], Brain Neoplasms/radiotherapy [MeSH], Follow-Up Studies [MeSH], Mutation [MeSH], Brain Neoplasms/secondary [MeSH], Adult [MeSH], Humans [MeSH], Melanoma/secondary [MeSH], Treatment Outcome [MeSH], Melanoma/radiotherapy [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], SRS, Prognosis [MeSH], Radiotherapy Dosage [MeSH], Brain Neoplasms/diagnostic imaging [MeSH], Radiotherapy Dosage, Middle Aged, Prognosis, ddc, Brain Metastases, Gpa, Prognostic Factors, Srs, 3. Good health, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Mutation, Humans, Female, Karnofsky Performance Status, Aged, Follow-Up Studies, Retrospective Studies

File Description: application/pdf

Access URL: https://link.springer.com/content/pdf/10.1007/s12094-021-02607-8.pdf
https://pubmed.ncbi.nlm.nih.gov/33993415
https://link.springer.com/article/10.1007/s12094-021-02607-8
https://pubmed.ncbi.nlm.nih.gov/33993415/
https://dialnet.unirioja.es/servlet/articulo?codigo=8062060
https://link.springer.com/content/pdf/10.1007/s12094-021-02607-8.pdf
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=62109
https://repository.publisso.de/resource/frl:6445606
https://mediatum.ub.tum.de/doc/1624398/document.pdf

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial: health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Authors: Bottomley A. Coens C. Mierzynska J. et al.

Contributors: Bottomley A. Coens C. Mierzynska J. et al.

Source: EORTC Melanoma Group 2021, 'Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial', The Lancet Oncology, vol. 22, no. 5, pp. 655-664. https://doi.org/10.1016/S1470-2045(21)00081-4
Lancet Oncology, 22, 5, pp. 655-664
Lancet. Oncology, Vol. 22, No 5 (2021) pp. 655-664
EORTC Melanoma Group 2021, 'Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial', The Lancet Oncology, vol. 22, no. 5, pp. 655-664. https://doi.org/10.1016/S1470-2045(21)00081-4

Subject Terms: Adult, Male, Melanoma / psychology, Skin Neoplasms / psychology, Skin Neoplasms, Antibodies, Monoclonal, Humanized / therapeutic use, Humanized/therapeutic use, Medizin, Skin Neoplasms / drug therapy, Antibodies, Monoclonal, Humanized, Antibodies, Melanoma / mortality, 03 medical and health sciences, Melanoma / pathology, Radboudumc 2: Cancer development and immune defence RIHS: Radboud Institute for Health Sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Double-Blind Method, Monoclonal, Skin Neoplasms/drug therapy, 80 and over, Humans, Melanoma/drug therapy, Skin Neoplasm, Middle aged, Humanized, Melanoma, Aged, Neoplasm Staging, ddc:616, Aged, 80 and over, Skin Neoplasms / pathology, Melanoma / drug therapy, Manchester Cancer Research Centre, Quality of Life, Humans [MeSH], Oncology and carcinogenesis, Middle Aged, Skin Neoplasms / mortality, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, 3. Good health, Antibodies, Monoclonal, Humanized/therapeutic use, Female

File Description: application/pdf; STAMPA

Access URL: https://pubmed.ncbi.nlm.nih.gov/33857414
https://research.manchester.ac.uk/en/publications/5f4dda20-295c-4eb2-8c2e-9f1e67d7f192
https://doi.org/10.1016/S1470-2045(21)00081-4
https://www.ncbi.nlm.nih.gov/pubmed/33857414
https://inrepo01.inet.dkfz-heidelberg.de/record/168977
https://findanexpert.unimelb.edu.au/scholarlywork/1518989-adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-%28eortc-1325-mg-keynote-054%29--health-related-quality-of-life-results-from-a-double-blind--randomised--controlled--phase-3-trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00081-4/fulltext
https://www.sciencedirect.com/science/article/pii/S1470204521000814
https://research.unipg.it/handle/11391/1492110
https://research.vumc.nl/en/publications/3a96aa01-a65e-4d39-b2e9-0c87a44be567
https://archive-ouverte.unige.ch/unige:159804
https://www.sciencedirect.com/science/article/pii/S1470204521000814
https://doi.org/10.1016/S1470-2045(21)00081-4
https://hdl.handle.net/11365/1233297
https://hdl.handle.net/11391/1492110
https://doi.org/10.1016/S1470-2045(21)00081-4
https://www.ncbi.nlm.nih.gov/pubmed/33857414
https://doi.org/10.1016/S1470-2045(21)00081-4
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85105831665
https://pure.rug.nl/ws/files/358617018/PIIS1470204521000814.pdf